WBB Securities analyst Stephen Brozak initiated coverage with a Buy rating on Caladrius Biosciences (CLBS) today and set a price target of $6.75. The company’s shares closed yesterday at $2.92, close to its 52-week low of $2.77.
Brozak wrote:
“We are therefore initiating coverage of CLBS with a Speculative Buy rating and a 12- month price target of $6.75.”
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 14.2% and a 47.5% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Marker Therapeutics Inc, RedHill Biopharma, and ADMA Biologics.
Caladrius Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $10.42, representing a 256.8% upside. In a report issued on May 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.50 price target.
See today’s analyst top recommended stocks >>
Based on Caladrius Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.37 million. In comparison, last year the company had a GAAP net loss of $4.98 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03.
